News
BIOCORP und NOVO NORDISK schließen weltweite Partnerschaft im Bereich Diabetes und digitale Gesundheit
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / PEA/KMU-qualifiziert), ein französisches Unternehmen mit Spezialisierung auf die Gestaltung, Entwicklung und Herstellung von innovativen
Sensorion Reports 2021 First Half Results
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage and gene therapy biotech company specializing in the development of novel therapies to restore, treat
BIOCORP and NOVO NORDISK Sign Global Partnership Within Diabetes on Digital Health
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, today
Valbiotis: Exklusivvereinbarung mit ADECAL Technopole und IFREMER stärkt Entwicklung innovativer natürlicher Gesundheitslösungen durch die Integration der Erforschung von Mikroalgen aus Neukaledonien
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur
Valbiotis Consolidates Its Development of Innovative Natural Health Solutions by Integrating the Exploration of Microalgae Produced in New Caledonia, Through an Exclusive Agreement With ADECAL-Technopole and IFREMER
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a French research and development company committed to scientific innovation for preventing and combating of metabolic
Regulators Approve Sensorion’s Amendment to Phase 2 AUDIBLE-S Trial of SENS-401 in Sudden Sensorineural Hearing Loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specialising in the development of novel therapies to restore, treat and prevent
BIOCORP und MERCK unterzeichnen Kooperationsvereinbarung auf dem Gebiet des menschlichen Wachstumshormons (HGH)
Aufsichtsrechtliche Meldungen:
BIOCORP (FR0012788065 – ALCOR / PEA/KMU-qualifiziert), ein französisches Unternehmen, das auf die Konzeption, Entwicklung und Herstellung von innovativen
BIOCORP and MERCK Sign a Partnership in the Field of Human Growth Hormone (HGH)
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, and Merck, a leading
GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Sensorion And Hearing Care Leader Sonova Sign Strategic Research Collaboration
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotech company specializing in the development of novel therapies to restore, treat, and prevent
Valbiotis Releases its Letter to Shareholders for 2021
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic
Valbiotis veröffentlicht Aktionärsbrief für 2021
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA/KMU-qualifiziert) (Paris:ALVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher
THERANEXUS AND BEYOND BATTEN DISEASE FOUNDATION (BBDF) WIN US INVESTIGATIONAL NEW DRUG (IND) APPROVAL TO START CLINICAL DEVELOPMENT OF BBDF 101
Lyon, 9 September 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and Beyond Batten Disease Foundation (BBDF), announce receipt of
GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908006154/en/
Figure 1. BCVA in untreated ND4-LHON patients as a
Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination With Cochlear Implantation
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology, which specializes in the development of novel therapies to restore, treat and prevent
Valbiotis meldet Abschluss der Rekrutierung für klinische Phase-II-Studie HEART für TOTUM•070 bei Hypercholesterinämie, einem Risikofaktor für kardiovaskuläre Erkrankungen
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA/SME-fähig), ein französisches Forschungs- und Entwicklungsunternehmen, das sich wissenschaftlichen Innovationen zur Prävention und
Valbiotis Announces the Completion of Recruitment for the Phase II HEART Clinical Study Conducted With TOTUM•070 in Hypercholesterolemia, a Risk Factor for Cardiovascular Disease
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a French research and development company committed to scientific innovation for preventing and combating metabolic diseases
UK MHRA Grants GenSight Biologics’ LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine Designation
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ®
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005575/en/
Figure 1. Evolution of best-corrected visual acuity
Sensorion Appoints Ex-Novartis Cell Therapy & Viral Vectors Head Otmane Boussif as Chief Technical Officer
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 JUNE 2021 AND PRESENTS AN UPDATE ON THE PROGRESS OF ITS MAIN PROGRAMS
Lyon, 8 July 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between
GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
GenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial, Confirming LUMEVOQ® Efficacy Including Better Efficacy with Bilateral Treatment
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629006120/en/
Figure 1. Best-Corrected Visual Acuity (BCVA) Change
Valbiotis kündigt Durchführung klinischer Studie zur Wirkungsweise von TOTUM-63 durch INAF1 an der Universität Laval in Quebec City in Kooperation mit Nestlé Health Science an
Valbiotis (FR0013254851 - ALVAL, PEA/SME-fähig), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von Stoffwechselkrankheiten
Valbiotis Announces the Implementation of the TOTUM•63 Mode of Action Clinical Study by INAF1 at Laval University in Quebec City, in Partnership With Nestlé Health Science
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases